ANI Pharmaceuticals Files 2024 10-K
Ticker: ANIP · Form: 10-K · Filed: Feb 28, 2025 · CIK: 1023024
| Field | Detail |
|---|---|
| Company | Ani Pharmaceuticals Inc (ANIP) |
| Form Type | 10-K |
| Filed Date | Feb 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financials
TL;DR
ANI Pharma's 2024 10-K is in. Check financials & risks.
AI Summary
ANI Pharmaceuticals Inc. filed its 2024 10-K on February 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, previously known as BioSante Pharmaceuticals Inc. and Ben Abraham Technologies Inc., is based in Baudette, MN. The filing includes information on business operations, financial performance, and risk factors relevant to its pharmaceutical preparations business.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of ANI Pharmaceuticals' financial health, strategic direction, and potential risks for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, ANI Pharmaceuticals faces inherent risks related to drug development, regulatory approvals, market competition, and intellectual property.
Key Numbers
- 2024 — Fiscal Year (Reporting period for the 10-K filing.)
- 1231 — Fiscal Year End (Indicates the end date of the reporting period.)
- 20250228 — Filing Date (Date the 10-K was submitted to the SEC.)
Key Players & Entities
- ANI PHARMACEUTICALS INC (company) — Filer
- 20241231 (date) — Fiscal Year End
- 20250228 (date) — Filing Date
- BAUDETTE, MN (location) — Company Headquarters
- BIOSANTE PHARMACEUTICALS INC (company) — Former Company Name
- BEN ABRAHAM TECHNOLOGIES INC (company) — Former Company Name
FAQ
What were the primary business segments of ANI Pharmaceuticals in fiscal year 2024?
The filing indicates ANI Pharmaceuticals operates in the Pharmaceutical Preparations industry (SIC code 2834), but specific segment details would require a deeper dive into the document's business section.
Did ANI Pharmaceuticals undergo any significant acquisitions or divestitures in the reported period?
The filing references 'BusinessCombinationContingentConsiderationArrangements' which suggests potential M&A activity or related liabilities, but specific transactions are not detailed in the provided header information.
What is the company's primary state of incorporation?
ANI Pharmaceuticals Inc. is incorporated in Delaware (DE).
What were the total liabilities reported as of the fiscal year end?
The filing references 'AccruedLiabilitiesCurrent' and 'OtherLiabilitiesNoncurrent', indicating the presence of current and non-current liabilities, but specific total dollar amounts are not in the header.
Are there any significant impairment charges mentioned in the filing?
Yes, the filing includes links to sections discussing 'ImpairmentOfIntangibleAssetsFiniteLivedAndIndefiniteLived', suggesting potential impairment charges were considered or recorded.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 28, 2025 regarding ANI PHARMACEUTICALS INC (ANIP).